86342 Federal Register / Vol. 89, No. 210 / Wednesday, October 30, 2024 / Notices 

CMS staff. SSA processes Medicare 

enrollments on behalf of CMS. Form 

Number: CMS–40B (OMB control 

number: 0938–1230); Frequency: Once; 

Affected Public: Individuals and 

Households; Number of Respondents: 

1,184,546; Total Annual Responses: 

1,184,546; Total Annual Hours: 292,820. 

(For policy questions regarding this 

collection contact Carla Patterson at 

410–786–8911 or Carla.Patterson@

cms.hhs.gov.) 

4. Type of Information Collection 

Request: Revision of a currently 

approved collection; Title of 

Information Collection: Application for 

Medicare Part A and Part B Special 

Enrollment Period (Exceptional 

Circumstances); Use: Section 1837(m) of 

the Social Security Act (the Act) 

provides authority for the Secretary of 

the Department of Health and Human 

Services to establish SEPs for 

individuals who are eligible to enroll in 

Medicare and meet such exceptional 

conditions as the Secretary may 

provide. 

CMS provides SEPs for individuals 

experiencing an exceptional 

circumstance to enroll in Medicare 

premium Part A and Part B. To utilize 

these SEPs, an individual would have to 

submit an enrollment request via the 

form CMS–10797. The form is used by 

individuals who have missed an 

enrollment period due to an exceptional 

circumstance to enroll in Part A and/or 

Part B. Individuals complete the form 

and submit it to SSA to complete the 

enrollment. 

The application form provides the 

necessary information to determine 

eligibility and to process the 

beneficiary’s request for enrollment in 

premium Part A or Part B due to an 

exceptional circumstance. The form is 

only used for enrollment by 

beneficiaries who could not enroll 

during another enrollment period due to 

an exceptional circumstance. Form 

Number: CMS–10797 (OMB control 

number: 0938–1426); Frequency: Once; 

Affected Public: Individuals and 

Households, Business or other forprofits, Not-for-profits institutions; 

Number of Respondents: 34,612; Total 

Annual Responses: 34,612; Total 

Annual Hours: 19,901. (For policy 

questions regarding this collection 

contact Carla Patterson at 410–786–8911 

or Carla.Patterson@cms.hhs.gov.) 

5. Type of Information Collection 

Request: Revision of a currently 

approved collection; Title of 

Information Collection: Request for 

Enrollment in Supplementary Medical 

Insurance (SMI); Use: Section 1836 of 

the Social Security Act, and CMS 

regulations at 42 CFR 407.10, provide 

the eligibility requirements for 

enrollment in Part B for individuals 

aged 65 and older who are not entitled 

to premium-free Part A. The individual 

must be a resident of the United States, 

and either a U.S. Citizen or an alien 

lawfully admitted for permanent 

residence that has lived in the US 

continually for 5 years. 

Part B is a voluntary program and is 

financed from premium payments by 

enrollees together with contributions 

from funds appropriated by the Federal 

government. All individuals age 65 or 

older who are entitled to Part A can 

enroll in Part B. There are some 

individuals, age 65 and over who are 

not entitled to or eligible for premiumfree Part A. These individuals may, 

however, enroll in Part B only. 

The CMS–4040 solicits the 

information that is used to determine 

entitlement for individuals who meet 

the requirements in section 1836 as well 

as the entitlement of the applicant or 

their spouses to an annuity paid by 

OPM for premium deduction purposes. 

The application follows the application 

questions and requirements used by 

SSA. This is done not only for 

consistency purposes but to comply 

with other title II and title XVIII 

requirements because eligibility to title 

II benefits and free Part A under title 

XVIII must be ruled out in order to 

qualify for enrollment in Part B only. 

Form Number: CMS–4040 (OMB control 

number: 0938–0245); Frequency: Once; 

Affected Public: Individuals and 

Households, Business or other forprofits, Not-for-profits institutions; 

Number of Respondents: 48,642; Total 

Annual Responses: 48,642; Total 

Annual Hours: 12,161. (For policy 

questions regarding this collection 

contact Carla Patterson at 410–786–8911 

or Carla.Patterson@cms.hhs.gov.) 

William N. Parham, III, 

Director, Division of Information Collections 

and Regulatory Impacts, Office of Strategic 

Operations and Regulatory Affairs. 

[FR Doc. 2024–25148 Filed 10–29–24; 8:45 am] 

BILLING CODE 4120–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Administration for Children and 

Families 

Proposed Information Collection 

Activity; Administration for Native 

Americans Project Outcome 

Assessment Survey (Office of 

Management and Budget #: 0970–0379) 

AGENCY: Administration for Native 

Americans, Administration for Children 

and Families, U.S. Department of Health 

and Human Services. 

ACTION: Request for public comments. 

SUMMARY: The Administration for 

Children and Families (ACF) is 

requesting a 3-year extension of the 

Administration for Native Americans 

Project Outcome Assessment Survey 

(OMB #: 0970–0379, expiration 6/30/ 

2025). The survey was revised based on 

a review by the Administration for 

Native Americans (ANA) and feedback 

from grantees, which identified some 

data elements that could be eliminated 

and areas that could be clarified. 

DATES: Comments due December 30, 

2024. In compliance with the 

requirements of the Paperwork 

Reduction Act of 1995, ACF is soliciting 

public comment on the specific aspects 

of the information collection described 

above. 

ADDRESSES: You can obtain copies of the 

proposed collection of information and 

submit comments by emailing 

infocollection@acf.hhs.gov. Identify all 

requests by the title of the information 

collection. 

SUPPLEMENTARY INFORMATION: 

Description: The information 

collected by the Project Outcome 

Assessment Survey is needed for two 

main reasons—(1) to collect crucial 

information required to report on ANA’s 

established Government Performance 

and Results Act (GPRA) measures and 

(2) to properly abide by ANA’s 

congressionally mandated statute (42 

U.S.C. 2991 et seq.) found within the 

Native American Programs Act of 1974, 

as amended, which states that ANA will 

evaluate projects assisted through ANA 

grant dollars ‘‘including evaluations that 

describe and measure the impact of 

such projects, their effectiveness in 

achieving stated goals, their impact on 

related programs, and their structure 

and mechanisms for delivery of 

services.’’ The survey information is 

requested once at the end of a project 

grant period. The information collected 

with this survey will fulfill ANA’s 

statutory requirement and will also 

serve as an important planning and 

performance tool for ANA. 

There are minor revisions proposed to 

the survey to align with ANA’s current 

requirements of grant recipients and 

eliminate duplicative data elements. 

Respondents: Tribal Governments, 

Native American nonprofit 

organizations, and Tribal Colleges and 

Universities. 


ddrumheller on DSK120RN23PROD with NOTICES1
Federal Register / Vol. 89, No. 210 / Wednesday, October 30, 2024 / Notices 86343 

ANNUAL BURDEN ESTIMATES

Instrument Number of 

respondents 

Number of 

responses per 

respondent 

Average 

burden hours 

per response 

Annual burden 

hours 

ANA Project Outcome Assessment Survey .................................................... 85 1 6 510 

Comments: The Department 

specifically requests comments on (a) 

whether the proposed collection of 

information is necessary for the proper 

performance of the functions of the 

agency, including whether the 

information shall have practical utility; 

(b) the accuracy of the agency’s estimate 

of the burden of the proposed collection 

of information; (c) the quality, utility, 

and clarity of the information to be 

collected; and (d) ways to minimize the 

burden of the collection of information 

on respondents, including through the 

use of automated collection techniques 

or other forms of information 

technology. Consideration will be given 

to comments and suggestions submitted 

within 60 days of this publication. 

Authority: 42 U.S.C. 2992. 

Mary C. Jones, 

ACF/OPRE Certifying Officer. 

[FR Doc. 2024–25139 Filed 10–29–24; 8:45 am] 

BILLING CODE 4184–34–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Government Owned Inventions 

Available for Licensing/Collaboration: 

Using Artificial Intelligence To 

Diagnose Uveitis 

AGENCY: National Institutes of Health, 

HHS. 

ACTION: Notice. 

SUMMARY: The National Eye Institute 

seeks (NEI), an institute of the National 

Institutes of Health (NIH), Department 

of Health and Human Services (HHS), is 

giving notice of the licensing and 

collaboration opportunity for the 

inventions listed below, which are 

owned by an agency of the U.S. 

Government and are available for 

licensing/collaboration in the U.S. to 

achieve expeditious commercialization 

of results of federally-funded research 

and development. 

FOR FURTHER INFORMATION CONTACT: 

Inquiries related to this licensing/ 

collaboration opportunity should be 

directed to: Hiba Alsaffar, Ph.D., 

Technology Transfer Manager, NCI, 

Technology Transfer Center, Email: 

hiba.alsaffar@nih.gov or Phone: 240– 

276–7489. 

SUPPLEMENTARY INFORMATION: Uveitis is 

caused by inflammation in the eye that 

can cause pain and reduce vision. The 

rate of uveitis in the United States is 1 

in every 200 people with eye-related 

irritation. Permanent symptoms such as 

vision loss can occur if untreated. 

Therefore, early detection is crucial. In 

certain uveitis cases, fluorescein 

angiography (FA) is essential for the 

diagnosis and management due to its 

ability to display retinal vascular 

leakage (RVL). Although proven to be 

critical in diagnosing and assessing 

severity, FA is invasive and side effects 

have been reported. Additionally, the 

procedure is time-consuming and 

imposes economic burdens to patients, 

physicians and payors. Scientists at the 

NEI have developed a deep learning tool 

to non-invasively detect RVL using 

ultrawide-field color fundus photos. 

This algorithm identifies fundus images 

with and without RVL with high 

accuracy (79%) and sensitivity (85%). 

Compared to the current gold standard 

of assessing RVL (clinician 

interpretation), this deep learning tool 

provides an improved method of 

detecting RVL for patients with uveitis. 

This Notice is in accordance with 35 

U.S.C. 209 and 37 CFR part 404. 

NIH Reference Number: E–005–2023– 

0. 

Potential Commercial Applications: 

• Diagnostic tool to predict uveitis. 

• Add-on to current color fundus 

imaging modalities. 

Competitive Advantages: 

• Greater accuracy and sensitivity 

versus current gold standard to assess 

RVL (clinician assessment). 

• Deep learning tool to assess RVL. 

• Deep learning to assess ultrawidefield color fundus images and assess 

RVL. 

Publication: Young LH, et al. 

Automated Detection of Vascular 

Leakage in Fluorescein Angiography—A 

Proof of Concept. (PMID 35877095). 

Patent Status: US Provisional 

Application 65/599,446 filed on 

November 15, 2023. 

Development Stage: Prototype. 

Therapeutic Area(s): Eye, Ear, Nose, 

Throat. 

Dated: October 24, 2024. 

Richard U. Rodriguez, 

Associate Director, Technology Transfer 

Center, National Cancer Institute. 

[FR Doc. 2024–25162 Filed 10–29–24; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Heart, Lung, and Blood 

Institute; Notice of Closed Meeting 

Pursuant to section 1009 of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of the 

following meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: Heart, Lung, and 

Blood Initial Review Group; NHLBI 

Institutional Training Mechanism Study 

Section. 

Date: December 6, 2024. 

Time: 10 a.m. to 6 p.m. 

Agenda: To review and evaluate grant 

applications. 

Address: National Institutes of Health, 

Rockledge I, 6705 Rockledge Drive, Bethesda, 

MD 20892. 

Meeting Format: Virtual Meeting. 

Contact Person: Michael P. Reilly, Ph.D., 

Scientific Review Officer, Office of Scientific 

Review/DERA, National Heart, Lung, and 

Blood Institute, National Institutes of Health, 

6705 Rockledge Drive, Room 208–Z, 

Bethesda, MD 20892, 301–827–7975, email: 

reillymp@nhlbi.nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.233, National Center for 

Sleep Disorders Research; 93.837, Heart and 

Vascular Diseases Research; 93.838, Lung 

Diseases Research; 93.839, Blood Diseases 

and Resources Research, National Institutes 

of Health, HHS) 


ddrumheller on DSK120RN23PROD with NOTICES1